← Back to Search

Asthma APGAR for Asthma (Asthma APGAR Trial)

Phase 4
Waitlist Available
Led By Barbara P Yawn, MD MSc
Research Sponsored by Olmsted Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 months
Awards & highlights

Asthma APGAR Trial Summary

Asthma is a common problem among US adults and children. Unfortunately many people with asthma continue to suffer from asthma symptoms that could be control with better asthma care and more attention to details such as triggers, and adherence. To date the only tools available and recommended by groups such as the national asthma guideline group consider only asthma burden and do not include information on the most common factors that adversely affect asthma control. This study provides one half of the enrolled primary care offices with the Asthma APGAR which is a system of patient completed questions and a care flow sheet. The other half of the enrolled practices will continue to provide "usual" care without the support of the Asthma APGAR system. The research questions is whether or not asthma control and asthma related quality of life will be improved in people with asthma who are cared for in the intervention practices that use the Asthma APGAR system.

Asthma APGAR Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Asthma Quality of Life Questionnaire (AQLQ)
Secondary outcome measures
Asthma Control Questionnaire
Exacerbation rate

Asthma APGAR Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Asthma APGARExperimental Treatment1 Intervention
Use of new asthma care tools. Primary care practices will be provided and educated about the Asthma APGAR tool system to guide asthma care. The practices will adopt this system for all people in their practices with asthma. Outcomes will be assessed only for those who meet enrollment criteria and sign informed consent.
Group II: Usual carePlacebo Group1 Intervention
Usual asthma care as provided by the sites.

Find a Location

Who is running the clinical trial?

Olmsted Medical CenterLead Sponsor
3 Previous Clinical Trials
4,149 Total Patients Enrolled
1 Trials studying Asthma
1,070 Patients Enrolled for Asthma
Barbara P Yawn, MD MScPrincipal InvestigatorOlmsted Medical Center
1 Previous Clinical Trials
3,000 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~111 spots leftby Apr 2025